| Literature DB >> 32449793 |
Xuqiang Nie1,2,3, Jiufeng Zhao1, Hua Ling4, Youcai Deng3, Xiaohui Li3, Yuqi He1,2.
Abstract
Diabetic chronic cutaneous ulcers (DCU) are one of the serious complications of diabetes mellitus, occurring mainly in diabetic patients with peripheral neuropathy. Recent studies have indicated that microRNAs (miRNAs/miRs) and their target genes are essential regulators of cell physiology and pathology including biological processes that are involved in the regulation of diabetes and diabetes-related microvascular complications. in vivo and in vitro models have revealed that the expression of some miRNAs can be regulated in the inflammatory response, cell proliferation, and wound remodelling of DCU. Nevertheless, the potential application of miRNAs to clinical use is still limited. Here, we provide a contemporary overview of the miRNAs as well as their associated target genes and pathways (including Wnt/β-catenin, NF-κB, TGF-β/Smad, and PI3K/AKT/mTOR) related to DCU healing. We also summarize the current development of drugs for DCU treatment and discuss the therapeutic challenges of DCU treatment and its future research directions.Entities:
Keywords: Diabetic chronic cutaneous ulcers; NF-κB signaling pathway; PI3K/AKT/mTOR signaling pathway; TGF-β/Smad signaling pathway; Wnt/β-catenin signaling pathway; microRNAs
Mesh：
Substances：
Year: 2020 PMID： 32449793 PMCID： PMC7443474 DOI： 10.1111/bph.15139
Source DB: PubMed Journal: Br J Pharmacol ISSN： 0007-1188 Impact factor: 8.739